RFL - Rafael Pharmaceuticals gives enrollment update of late-stage leukemia trial

Rafael Pharmaceuticals (RFL) announces that it has crossed the enrollment of 150 patients in its Phase 3 clinical trial for patients with relapsed or refractory acute myeloid leukemia ((AML)).The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613 (devimistat) in combination with high dose cytarabine and mitoxantrone ((CHAM)) compared to high dose cytarabine and mitoxantrone ((HAM)) therapy in older patients.The FDA had designated Fast Track status to Rafael's CPI-613 (devimistat), for the treatment of acute myeloid leukemia, in December last year.

For further details see:

Rafael Pharmaceuticals gives enrollment update of late-stage leukemia trial